Background: There are currently no biomarkers for early breast cancer patient populations at risk of bone metastasis. Identification of mediators of bone metastasis could be of clinical interest.
article and anti-HER2 therapy (in HER2-positive tumors), may eradicate micrometastatic disease and thereby reduce the risk of metastatic relapse. However, current adjuvant treatments are toxic (particularly chemotherapy), only benefit a subset of women, and the prevention of overt metastasis is non-organ specific. BC is a highly heterogeneous disease, and there is clinical evidence of distinct patterns of disease relapse (1) . In fact, the capacity of metastatic BC cells to grow in different environments may give rise to metastatic speciation (2) .
The discovery in past years of mediators of organ-specific metastasis in breast and other cancers suggests that it might be possible to identify clinically actionable biomarkers that specifically predict bone metastasis risk in breast cancer. Unbiased testing for recurrent copy number aberrations (CNAs) in large datasets aimed at the identification of bone metastasis risk mediators is a feasible approach that may provide novel data and insights. CNAs have been observed in several human cancers, and these events are usually associated with the presence of mediators of malignancy and clinical outcome, for example 17q12 and the HER2 oncogene (3). However, CNAs associated with tissue-specific metastasis remained uncharacterized.
Here we followed an unbiased screening approach to test the hypothesis that BC metastasizes to the bone by selecting mediators for homing, survival, and colonization that result from genomic alterations. Using this approach, we identified that the 16q23 gain, through the v-maf avian musculoaponeurotic fibrosarcoma oncogene homolog (MAF) gene, mediates bone metastasis in breast cancer and independently associates with risk of bone metastasis but not metastasis to other sites.
Methods

Cell Culture
The MCF7, ZR-75, and T47D human breast cancer (BC) cell lines and 4T1 murine BC cells were purchased from American Type Culture Collection (ATCC). These cell lines and their genetically modified derivatives were maintained as described previously (4) . Cells were maintained in the indicated media as per ATCC guidelines and were routinely tested for well-reported breast cancer markers, including estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). Thus, cells were grown in DMEM or RPMI medium (Gibco), supplemented with 10% fetal bovine serum (FBS) (Biological Industries Kibbutz Beit Haemek, Israel), Glutamine 0.29 mg/mL (Biological Industries Kibbutz Beit Haemek, Israel), Penicillin 100 U/mL (Biological Industries) and Streptomycin 0.1 mg/mL (Biological Industries Kibbutz Beit Haemek, Israel). Further details are given in the Supplementary Methods (available online).
Animal Studies and Xenografts
All animal work was approved by the institutional animal care and use committee of Institute for Research in Biomedicine (IRB) Barcelona and performed following the principles of laboratory animal care (as mandatory per European Union and Local government laws). Female BALB/c nude mice of 11 weeks of age (n = 9-37 per group) were used for all studies. Mice were anesthetized with ketamine (100 mg/kg body weight) and xylazine (10 mg/kg body weight), and after injection imaged mice were monitored weekly using IVIS imaging. Further details are given in the Supplementary Methods (available online).
Oligonucleotide Array Assays
RNA sample collection and generation of biotinylated complementary RNA (cRNA) probe were carried out essentially as described in the standard Affymetrix (Santa Clara, CA) GeneChip protocol. Ten micrograms of total RNA were used to prepare a cRNA probe using a Custom Superscript Kit (Invitrogen Carlsband, CA). For expression profiling, 25 ng of RNA per sample was processed using isothermal amplification SPIA Biotin System (NuGEN technologies San Carlos, CA). Each sample was hybridized with an Affymetrix Human Genome U133APlus2.0 microarray at the IRB Barcelona Functional Genomics Core Facility. Further details are given in the Supplementary Methods (available online).
Analysis of Copy Number Alterations in Expression Data
The detection of CNAs by means of expression profile analysis is based on strong correlation between the genomic alterations and the aberrant gene expression in the affected genomic regions. While the detection of CNAs using gene expression analysis is possible, difficulties arise from the type of starting expression data (8) . We used the function findCopyNumber from the Bioconductor phenoTest package, which implements an approach similar to the one applied by Hu et al. (5) to find regions with CNAs in the MSKCC/EMC cohort. Enrichment scores (in our case log hazard ratios) and the chromosomal positions of the scores allowed us to distinguish areas in which the enrichment was higher/lower than expected when the positions were assigned at random. Further details are given in the Supplementary Methods (available online).
Fluorescence in Situ Hybridization and Other Methods
Cells were processed as described (6) . The slides were incubated with MAF probe BAC RP11-1068n20. This probe covered a 197 kb segment at chr16: 79,460,645-79,657,297, a region including the full MAF gene (chr16: 79,625,745 to 79,639,622, 14 kb) and excluding WWOX and the FRA16D fragile site. In parallel, a CEP16 (centromeric chr16, 16q11.2) (Abbot Chicago, IL) probe was used to score 16q23 CNAs. Findings were confirmed with an independent MAF/CEP16 probe (Inbiomotion Barcelona, Spain). DAPI counterstain was applied, and images were acquired with a Leica TCS-SP5 confocal microscope. The percentage of 16q23 CNA-positive cells was determined based on minimum of 100 counted cells for each condition. Information on protein extraction and western blots, chromatin immunoprecipitation, quantitative real-time polymerase chain reaction (qRT-PCR), histopathology and immunohistochemistry, reporter assays, osteoclast differentiation assay, and cell migration and adhesion assays is given in the Supplementary Methods (available online).
Patient Gene Expression Datasets
Information on the patients was downloaded from GEO (7) . The following cohorts were used: A) MSKCC/EMC. Pooled GSE2603, GSE2034, and GSE12276; B) GSE14020. ER+ patients were selected on the basis of the bimodality of gene ESR1. C) Patient expression profiles and clinical annotations were downloaded as described in van de Vijver et al. (8) . Further details are given in the Supplementary Methods (available online).
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Statistical Methods
Cumulative incidence was estimated with Cox proportional hazard models and likelihood ratio tests. The assumption of proportionality was checked using the supremum test for proportional hazards assumption. This test yields a significant P value if this assumption is violated.
Of note, cumulative incidence for validation dataset II was calculated using Cox cause-specific hazard model with competing events (death). Cumulative incidence functions for recurrence were estimated. These functions estimate the actual percentage of patients who will experience the various competing events within the study cohorts as opposed to the overestimated percentages obtained with the Kaplan-Meier method based on the cause-specific hazards.
For survival analyses, a multivariable Cox proportional hazard model was fitted to test the correlation between high MAFexpressing vs the rest of the tumors and bone metastasis. Tumor size, lymph node status, tumor grade, and proliferation were used as adjustment variables. R's function step was used to perform backward elimination by AIC. P values were obtained with Cox proportional hazards likelihood ratio tests.
The Wilcoxon rank-sum test was used to assess the agreement of immunohistochemistry (IHC) and florescence in situ hybridization (FISH) events in each sample and Pearson correlation was used to estimate the correlation of IHC and FISH events. Data were analyzed using R as well as Prism 6 (GraphPad Software Inc.). All statistical tests were two-sided.
Results
Identification of CNAs Associated With Bone Metastasis in BC
We developed an experimental xenograft mouse model based on ER+ moderately bone metastatic MCF7 BC cells to derive cells with higher propensity to metastasize to the bone (9) (10) (11) (12) (13) (14) . To perform in vivo selection we introduced MCF7 luciferase-expressing Figure 1A) . The tumor growth when tested by orthotopic injection at the mammary fat pad was similar between parental MCF7 and BoM2 cells, and both were dependent on estrogen gene responses (Supplementary Figure 1 , A-C, available online).
We studied genomic copy number aberrations (CNAs) in BoM2 cells by comparative genomic hybridization. We uncovered substantial losses in chromosomes 6, 12, 19, 20 , and 21 and one substantial gain (16q22-q24) in BoM2 compared with the parental population ( Figure 1B ; Supplementary Figure 1D , available online). Using an ACE-like algorithm (Analysis of CNAs by Expression data [5] ), we associated variations in CNA with metastasis risk in 349 ER+ primary BC patients (discovery MSKCC/EMC BC set) (12) . Only the 16q22-24 chromosomal gain showed a substantial association with metastasis ( Figure 1C ; Supplementary Figure 1E , available online). This association was confirmed by applying the ACE-like algorithm to an independent validation cohort I (van de Vijver BC set) ( Figure 1C ) (8) .
Patients with 16q22-24 CNA-positive ER+ BC tumors (MSKCC/ EMC) had a higher cumulative rate of metastasis (hazard ratio
[HR] = 1.37, 95% confidence interval [CI] = 1.01 to 1.88, P = .048) (Supplementary Figure 1F , available online). Next, we confirmed 16q23 copy gain in BoM2 cells (98.7% of cells) compared with parental MCF7 cells (8.7% of cells) by means of the ratio of a 16q23 and a CEP16 (16q11.2) centromeric FISH probe ( Figure 1D ). We also characterized additional breast cancer cell lines and showed that they had varying degrees of 16q23 gain (T47D 13.7% and ZR-75 47.5%) (Supplementary Figure 1G , available online).
Association of 16q23 Genomic Gain With Breast Tumors That Develop Bone Metastasis
Next, we tested 16q23 gain by FISH in paraffin-embedded samples from an independent validation set II of primary stage I-III BC specimens from patients with annotated clinical follow-up (Spanish dataset) (15) . We found that 14% of the 334 primary BCs tested were classified as positive for 16q23 gain, defined by at least 1.5 copies of the 16q23 region normalized to the CEP16 centromeric probe per cell (a minimum of 50 cells per specimen were scored) ( Figure 1E ). 16q23 gain-positive tumors were at a high cumulative incidence rate of bone metastasis at any time (HR = 14.5, 95% I = 6.4 to 32.9, P < .001; hazard ratio was calculated considering death before recurrence in bone as a competing event) ( Table 1 and Figure 1F ; Supplementary Tables 1 and 2, The risk of the competing event is reported in Supplementary Table 2 (available online) . CI = confidence interval; CNA = copy number aberration; HER2 = human epidermal growth factor receptor 2; HR = hazard ratio. Figure 1J , available online), with a 97% negative predictive value (NPV). The relationship between 16q23 gain and bone metastasis was statistically significant in ER+, triple-negative (TN), and HER2+ tumors ( Figure 1F ; Supplementary Figure 1K , available online).
Association of MAF Expression in the 16q23 Region With Bone Metastasis
We examined possible bone mediators in the 16q23 region by identifying genes that were more than two-fold (P < .05) differentially expressed in BoM2 derivatives compared with parental MCF7 cells (Supplementary Figure 2A, available online) . Among the two candidates, MAF and SLC9A5 (Supplementary Figure 2, A-D, available online), the Cox hazard ratio for the association of mRNA expression and bone metastasis showed statistical significance for MAF (P = .032) but not for the SLC9A5 (P = .95) (MSKCC/EMC BC dataset). Patients with BC with high MAF expression showed a greater cumulative incidence of metastasis to bone-but not to brain or lung-than the rest (HR for bone metastasis = 2.5, 95% CI = 1.7 to 3.8, P < .001) (Figure 2A ; Supplementary Figure 2E , available online). Next, we confirmed MAF gain in 9.1% of the 1079 tumors evaluated by the The Cancer MAF is measured at the mRNA level (discovery set) and protein level (validation set). BC = breast cancer; CI = confidence interval; ER = estrogen receptor; HER2 = human epidermal growth factor receptor 2; HR = hazard ratio; OD = optical density.
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Genome Atlas BC project (16) . This percentage was smaller than in the FISH validated Spanish dataset II; however, this may be related, at least in part, to the higher sensitivity of our test. MAF, a potential genetic driver of the 16q23 region, is a transcription factor of the AP-1 family that has been reported to contribute to transformation in 60% of Angioimmunoblastic T-cell lymphoma (AITL) (17, 18) and 50% of multiple myeloma (MM) patients (19) . However, to date, MAF has not been associated with BC cell transformation, tumor progression, or metastasis (20) .
To characterize the relationship between MAF and bone metastasis, we analyzed MAF protein expression by immunohistochemistry in the validation dataset II (high MAF defined as >1000 optical density [OD], cutoff determined based on the receiver operating characteristic curve) ( Figure 2B ; Supplementary Figure 2F , available online). High MAF protein staining associated with a high cumulative risk of metastasis to bone at any time but not to other nonvisceral and visceral sites (HR for bone metastasis = 4.68, 95% CI = 2.29 to 9.57, P < .001) ( Figure 2C and Table 2; Supplementary Tables 3 and 4 , available online). MAF protein expression by IHC and 16q23 gain by FISH were correlated (r = 0.52, P < .001) ( Figure 2D ; Supplementary Figure 2G , available online). MAF protein expression enabled better assignment of positive bone metastasis patients than MAF mRNA expression ( Figure 2E ). ER+ BC patients with MAF OD above 25 000 developed bone metastasis with almost complete penetrance (sensitivity = 0.36, specificity = 0.99, HR for bone met at any time = 21.3, 95% C.I = 8.3 to 54.7, P < .001) (Supplementary Figure 2H, available online) . In triple-negative disease, 1000 OD cutoff-identified patients at high risk of bone metastasis (sensitivity = 0.75, specificity = 0.83; HR for bone met at any time = 10.7, 95% CI = 2.2 to 53.3, P = .001) (Supplementary Figure 2H, available online) . In HER2+ patients, no statistical significance was achieved (Supplementary Figure 2I, available  online) . In a multivariable analysis, MAF protein expression retained its predictive value for bone metastasis independently of traditional clinico-pathological parameters (HR for bone metastasis at any time = 5.28, 95% CI = 2.5 to 11.2, P < .001) ( Table 2; Supplementary Tables 3 and 4 , available online).
Effect of MAF on BC Metastasis to Bone
Next, we functionally validated the role of MAF in bone metastasis by MAF-stable downregulation or overexpression in a panel of BC cell lines. Interestingly, MAF protein levels in the 16q23 gain-positive BoM2, MCF7 MAF-overexpressing, and ZR-75 cells were comparable with those in 16q23 gain-positive tumors, whereas MCF7 parental, MAF-depleted BoM2, and T47D cells expressed MAF similarly to 16q23 gain-negative Similar results were observed in T47D cells that are poorly metastatic (9, 10) . Inoculation of T47D MAF-overexpressing cells statistically significantly reduced bone metastasis-free survival ( Figure 3E; Supplementary Figure 3, A, B , and M, available online) but did not influence metastasis rate in other sites (Supplementary Figure 3, N and O, available online) . Upon intibiae implantation, MAF expression increased bone colonization of T47D (ER+) ( Figure 3F ) and 4T1 (triple-negative) cells (Supplementary Figure 3P , available online), whereas MAF depletion in ZR75 (ER+) cells impaired this process ( Figure 3G ). Collectively, these results confirmed MAF as a mediator of bone metastasis in the various BC cells. tumors (>300 or >100 mm 3 for MCF7 or T47D, respectively) at day 42 were considered when evaluating bone metastasis. Individual tumors are represented as box plots with median, interquartile range, and min and max values. Bone colonization incidence is plotted. P value scored by two-sided Wilcoxon signed-rank test. C) Schematic representation of injection via left ventricle. Kaplan-Meier curve of bone metastasis-free survival for BoM2 shControl, shMAF, and rescue cells. P value was obtained using two-sided log-rank test. Representative bioluminescent images and hematoxylin and eosin (H&E) staining at days 0 and 54 (endpoint) of bone metastasis for each group are shown. T = tumor area. 500 and 50 μm scale bars were used for middle and right panels, respectively. Histomorphometric analysis of bone metastasis lesions is depicted (BV = bone area; TV = tumor area). P values scored by two-sided Wilcoxon signed-rank test, *<.05, **<.01, ***<.001. D) Kaplan-Meier curves of bone metastasis-free survival for MCF7 parental and MAF-overexpressing cells injected via left ventricle of mice. P value was obtained using two-sided log-rank test. E) Kaplan-Meier curve of bone metastasis-free survival for T47D parental and MAF-expressing cells injected via left ventricle of mice. P value was obtained using two-sided log-rank test. 
MAF-Induced BC Cell-Bone Stroma Interactions
We combined two independent analyses to identify genes that were transcriptional targets of MAF-short and/or -long isoforms and whose expression in a BC metastasis sample set was significantly correlated with MAF expression. First, we identified genes significantly up or downregulated upon MAF-short and/or -long overexpression in MCF7 cells. Subsequently, we eliminated those genes in the list whose expression was not significantly correlated (P ≥ .05) with MAF expression in BC metastasis patient samples (GSE14020; liver, brain, bone, and lung BC metastasis sample dataset) ( Figure 4A ) (21) . The resulting 148 putative MAF target genes were named MAF metastasis program (Supplementary  Table 5 , available online), and, of those, 25 genes were common targets of MAF-short and -long isoforms ( Figure 4A ; Supplementary Figure 4A , available online). The expression pattern of some of these genes in MAF-expressing cells was confirmed by qRT-PCR analysis ( Figure 4B ). These results suggested that MAF transcriptionally controls a collection of events that may broadly support functions required for bone metastasis, such as migration ( Figure 4C; Supplementary Figure 4B) , adhesion to bone marrow-derived cells ( Figure 4D ), and osteoclast differentiation ( Figure 4E ; Supplementary Figure 4C , available online).
In size-matched bone metastatic lesions, MAF expression resulted in an increased number of activated tartrate-resistant acid phosphatase multinucleated osteoclasts (TRAP+ cells) along the lesion perimeter ( Figure 5A ). We then examined the known mediator of bone stroma-tumor interactions PTHrP (parathyroid hormone-related protein) (22) that is one of the MAF metastasis program genes ( Figure 5B; Supplementary Figures 4A  and 5A , available online) (23, 24) . Bone metastasis co-expressed high MAF and PTHrP in 77% of the specimens tested ( Figure 5C ). MAF-enhanced induction of osteoclast differentiation from bone marrow-derived cells in vitro was suppressed upon co-incubation with a PTHrP antagonist peptide (PTHrP-AN) (Supplementary Figure 4C, available online) . Conditioned media from the indicated cellular populations were used. Data are means from three independent experiments with SD. P value scored by two-sided Wilcoxon signed-rank test.
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Previous studies showed that both MAF and PTHrP play a role in chondrocyte formation (25, 26) , thus suggesting a potential relationship between these genes. We addressed whether PTHrP and MAF had direct interaction in bone metastasis and/ or human BC, because this possibility had not been reported to date. We confirmed that the -3401/-2421bp PTHrP P1 promoter, containing a MARE-binding region, increased activity by overexpression of MAF. No effect of MAF on other PTHrP promoter regions was seen ( Figure 5, D and E) . Mutations that disrupt all MARE binding sites (Mutant 6) abrogated PTHrP P1 promoter response to MAF ( Figure 5F ). Evidence of a direct interaction was obtained by chromatin immunoprecipitation (ChIP) analysis, with MAF binding observed at P1 but not at the P2/3 proximal promoter region ( Figure 5G) .
Next, we sought to validate the contribution of PTHrP to MAF-driven bone metastasis in BC cells. We reduced PTHrP function in MAF-expressing MCF7 cells by shRNA (Supplementary Figure 5B , available online) or used systemic PTHrP-AN. MAFexpressing PTHrP-depleted cells had impaired ability to form bone metastases but not metastases at other sites ( Figure 6A ;
Supplementary Figure 5C, available online) . Similarly, PTHrP downregulation blunted the capacity of BoM2 cells to colonize the bones ( Figure 6B ) but not other distant sites (Supplementary Figure 5D , available online). Consistent with the concept that the interaction of breast cancer cells with the niche was central to MAF-mediated bone colonization, depletion of PTHrP or treatment with PTHrP-AN in BoM2 and MCF7/MAF-overexpressing cells not only decreased the number of bone metastasis but also osteoclasts (TRAP+ cells) along the lesion perimeter ( Figure 6 , C-E; Supplementary Figure 5 , E and F, available online). Collectively, these results support the hypothesis that MAF-mediated PTHrP expression is an important factor for the MAF-driven metastasis tumor cell-stroma interactions that foster BC bone metastasis.
Discussion
We provide novel evidence on the association of 16q23 gain to high risk of bone relapse in patients with early BC. We also show that MAF, a gene within this genomic gain, drives the molecular processes of bone colonization. Interestingly, the acquisition of article high MAF expression parallels that observed in MM and AITL, where several copies of the MAF genomic region or a t (14, 16) translocation are gained, leading to transformation and aggressive osteolytic bone colonization (20) . These observations suggest that the biology of metastasis mechanisms to the bone may rely on a common mediator that exerts similar or different functions depending on the tumor of origin.
Our results show that MAF controls the expression of a set of genes that collectively support several steps of BC cell metastasis to bone through a series of cell-autonomous and niche-related functions (27) . These observations open up the possibility of using MAF as a molecular target for the prevention or treatment of bone metastasis (28) . Among the MAF target genes, we identified PTHrP. Whereas PTHrP expression in primary tumors is associated with risk of bone metastasis in T4 and positive nodal status-primary BC (29) , it failed to predict bone metastasis in early stage breast tumors (30) . These results suggest that PTHrP per se is not sufficient to trigger bone metastasis in early stage BC unless a higher degree of transformation (T4 and positive nodal status) is present. Consistently, our results suggest that only within the right context, for example MAF gain leading to the acquisition of various functions that support bone metastasis such as migration, adhesion, etc., does PTHrP expression become an advantage to cancer cells that colonize the bone.
This study also had some limitations. Currently there are no mouse models of breast cancer bone metastasis, making it difficult to extrapolate our experimental results into the clinical setting. In addition, in some of the models analyzed we scored for metastatic bone colonization rather than metastasis from the breast primary site to the bone. Thus, particular focus on the late steps of colonization was unavoidable. The identification of novel drivers of breast cancer bone metastasis, being tested in clinically relevant samples, allows overcoming these limitations.
Our preclinical findings, as well as results from a clinical discovery series, led us to test 16q23 gain by FISH in paraffinembedded samples from patients with primary BC and clinical follow-up. We detected 16q23 CNA in 14% of a total of 334 article primary BC specimens and showed that it had a statistically significant and independent association with the risk of bone metastasis. This observation is in agreement with the expected frequency of BC patients who develop bone metastasis (10%-20%) after a 15-year follow-up (1, 31) . The 16q region contains a welldefined fragile site (FRA16) located at the FOR (WWOX) locus (32) . Alterations on FRA16 are observed in various tumor types with diverse clinical outcome associations; 16q loss of heterozygosity (33) , as well as 1q gain/16q loss (34) , was associated with a positive outcome in luminal BC (3); 16q loss was related to prostate cancer progression (35) , and 16q gain with poor outcome in MM (19) . In tumor cells, fragile sites have been associated with translocations, deletions, amplifications, and integration sites (36, 37) , which might explain the promiscuity of this region.
In addition, we developed an immunohistochemical assay to detect MAF expression. In primary tumors, MAF protein levels measured by IHC and 16q23 gain by FISH were significantly correlated, and both were associated with a high cumulative incidence of metastasis to bone but not to other nonvisceral or visceral sites. On the basis of the mechanistic and clinical data presented above, we propose that the 16q23 gain is selectively associated with bone metastasis risk in early-stage BC and that MAF encoded within this region mediates BC metastasis to bone ( Figure 6F ). This novel finding may enable the identification of patients at high risk of bone metastasis in a timely fashion. Clinical trials involving thousands of patients have tested or are currently testing the capacity of bisphosphonates or denosumab to prevent bone metastasis. The results of these trials have not yet influenced routine clinical practice (38) (39) (40) . In an era of personalized medicine, the incorporation of a biomarker to identify those individuals most likely to benefit from bone-targeted agents is urgently needed (41) . Testing 16q23 gain and MAF protein expression in breast cancer specimens from patients included in these trials to assess their predictive value to select patients who benefit from adjuvant bone-modified agents is warranted (42) . 
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